Zoetis Inc. $ZTS Shares Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 647.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,834 shares of the company’s stock after buying an additional 23,244 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Zoetis were worth $3,903,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Savvy Advisors Inc. grew its holdings in shares of Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after purchasing an additional 1,961 shares during the period. CIBC Asset Management Inc increased its stake in Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after purchasing an additional 10,434 shares in the last quarter. Nordea Investment Management AB raised its holdings in Zoetis by 10.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock worth $368,245,000 after buying an additional 214,889 shares during the period. Finally, Ninety One UK Ltd lifted its stake in Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after buying an additional 183,686 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a research report on Monday, December 15th. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Finally, Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $152.45.

Zoetis Stock Up 0.7%

ZTS stock opened at $128.13 on Wednesday. The company has a 50 day moving average of $124.03 and a two-hundred day moving average of $135.84. The company has a market cap of $56.47 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 2.20 and a beta of 0.96. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s payout ratio is 35.69%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.